(Q34633714)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22089421%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

title

Gastrointestinal stromal tumours: origin and molecular oncology (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22089421%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22089421%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

author name string

Christopher L Corless

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22089421%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Christine M Barnett

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22089421%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

language of work or name

English

0 references

publication date

17 November 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22089421%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

published in

Nature Reviews Cancer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22089421%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22089421%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22089421%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

page(s)

865-878

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22089421%20AND%20SRC:MED&resulttype=core&format=json

Gastrointestinal stromal tumors in a cohort of Chinese patients in Hong Kong

16 January 2020

cites work

1 reference

Incidence of gastrointestinal stromal tumours is underestimated: results of a nation-wide study

31 March 2020

1 reference

Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era--a population-based study in western Sweden

31 March 2020

1 reference

Gastrointestinal stromal tumors in Iceland, 1990-2003: the icelandic GIST study, a population-based incidence and pathologic risk stratification study.

31 March 2020

1 reference

Clinical management of gastrointestinal stromal tumors: before and after STI-571.

31 March 2020

1 reference

Gain-of-Function Mutations of c- kit in Human Gastrointestinal Stromal Tumors

31 March 2020

1 reference

The protein kinase family: conserved features and deduced phylogeny of the catalytic domains

31 March 2020

1 reference

The hematopoietic growth factor KL is encoded by the Sl locus and is the ligand of the c-kit receptor, the gene product of the W locus

31 March 2020

1 reference

Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase

31 March 2020

1 reference

KIT gene deletions at the intron 10-exon 11 boundary in GI stromal tumors

31 March 2020

1 reference

Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas

31 March 2020

1 reference

Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors

31 March 2020

1 reference

Gastrointestinal stromal tumors with KIT exon 11 deletions are associated with poor prognosis

31 March 2020

1 reference

Prognostic value of KIT mutation in gastrointestinal stromal tumors

31 March 2020

1 reference

Deletions affecting codons 557-558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS).

31 March 2020

1 reference

Analysis of CD117-negative gastrointestinal stromal tumors

31 March 2020

1 reference

Deletion of Trp-557 and Lys-558 in the juxtamembrane domain of the c-kit protooncogene is associated with metastatic behavior of gastrointestinal stromal tumors

31 March 2020

1 reference

KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors

31 March 2020

1 reference

Structural basis for activation of the receptor tyrosine kinase KIT by stem cell factor

31 March 2020

1 reference

Gene expression in gastrointestinal stromal tumors is distinguished by KIT genotype and anatomic site

31 March 2020

1 reference

Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: a multicenter study on 54 cases

31 March 2020

1 reference

STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications

31 March 2020

1 reference

Gastrointestinal stromal tumors in a mouse model by targeted mutation of the Kit receptor tyrosine kinase

31 March 2020

1 reference

A knock-in mouse model of gastrointestinal stromal tumor harboring kit K641E.

31 March 2020

1 reference

Polyclonal nature of diffuse proliferation of interstitial cells of Cajal in patients with familial and multiple gastrointestinal stromal tumours

31 March 2020

1 reference

Gastrointestinal stromal tumors: insights from a new familial GIST kindred with unusual genetic and pathologic features

31 March 2020

1 reference

Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs).

31 March 2020

1 reference

Oncogenic Kit signaling and therapeutic intervention in a mouse model of gastrointestinal stromal tumor

31 March 2020

1 reference

Protein Kinase C theta (PKCtheta) expression and constitutive activation in gastrointestinal stromal tumors (GISTs).

31 March 2020

1 reference

ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours

31 March 2020

1 reference

ERK/p90(RSK)/14-3-3 signalling has an impact on expression of PEA3 Ets transcription factors via the transcriptional repressor capicúa

31 March 2020

1 reference

KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway

31 March 2020

1 reference

Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor.

31 March 2020

1 reference

17-Allylamino-17-demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells

31 March 2020

1 reference

PDGFRalpha- and c-kit-mutated gastrointestinal stromal tumours (GISTs) are characterized by distinctive histological and immunohistochemical features

31 March 2020

1 reference

Neoplasia driven by mutant c-KIT is mediated by intracellular, not plasma membrane, receptor signaling.

31 March 2020

1 reference

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

31 March 2020

1 reference

Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation

31 March 2020

1 reference

Evolution from heterozygous to homozygous KIT mutation in gastrointestinal stromal tumor correlates with the mechanism of mitotic nondisjunction and significant tumor progression.

31 March 2020

1 reference

PDGFRA activating mutations in gastrointestinal stromal tumors.

31 March 2020

1 reference

Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors.

31 March 2020

1 reference

Differential expression of KIT/PDGFRA mutant isoforms in epithelioid and mixed variants of gastrointestinal stromal tumors depends predominantly on the tumor site

31 March 2020

1 reference

Correlation of KIT and platelet-derived growth factor receptor alpha mutations with gene activation and expression profiles in gastrointestinal stromal tumors

31 March 2020

1 reference

The platelet-derived growth factor receptor alpha is destabilized by geldanamycins in cancer cells.

31 March 2020

1 reference

Gastrointestinal stromal tumours (GISTs) negative for KIT (CD117 antigen) immunoreactivity

31 March 2020

1 reference

The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status

31 March 2020

1 reference

Array CGH analysis in primary gastrointestinal stromal tumors: Cytogenetic profile correlates with anatomic site and tumor aggressiveness, irrespective of mutational status

31 March 2020

1 reference

Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations have distinct gene expression profiles

31 March 2020

1 reference

KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications

31 March 2020

1 reference

Myxoid epithelioid gastrointestinal stromal tumor (GIST) with mast cell infiltrations: a subtype of GIST with mutations of platelet-derived growth factor receptor alpha gene

31 March 2020

1 reference

Association of platelet-derived growth factor receptor alpha mutations with gastric primary site and epithelioid or mixed cell morphology in gastrointestinal stromal tumors

31 March 2020

1 reference

A great majority of GISTs with PDGFRA mutations represent gastric tumors of low or no malignant potential

31 March 2020

1 reference

GISTs with PDGFRA exon 14 mutations represent subset of clinically favorable gastric tumors with epithelioid morphology

31 March 2020

1 reference

BRAF mutation status in gastrointestinal stromal tumors.

31 March 2020

1 reference

Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations

31 March 2020

1 reference

SDHA loss-of-function mutations in KIT-PDGFRA wild-type gastrointestinal stromal tumors identified by massively parallel sequencing

31 March 2020

1 reference

The genetic basis of kidney cancer: a metabolic disease

31 March 2020

1 reference

Germline SDHB mutations and familial renal cell carcinoma.

31 March 2020

1 reference

Gastrosplenic fistula from Hodgkin's lymphoma

31 March 2020

1 reference

NF1-associated gastrointestinal stromal tumors have unique clinical, phenotypic, and genotypic characteristics.

31 March 2020

1 reference

Multiple gastrointestinal stromal tumors: Clinicopathologic and genetic analysis of 12 patients

31 March 2020

1 reference

Molecular pathogenesis of multiple gastrointestinal stromal tumors in NF1 patients

31 March 2020

1 reference

Gastrointestinal stromal tumors in patients with neurofibromatosis 1: a clinicopathologic and molecular genetic study of 45 cases

31 March 2020

1 reference

Mitotic recombination as evidence of alternative pathogenesis of gastrointestinal stromal tumours in neurofibromatosis type 1.

31 March 2020

1 reference

Absence of c-kit gene mutations in gastrointestinal stromal tumours from neurofibromatosis type 1 patients

31 March 2020

1 reference

Gastrointestinal stromal tumors in children and young adults: a clinicopathologic, molecular, and genomic study of 15 cases and review of the literature

31 March 2020

1 reference

Pediatric KIT wild-type and platelet-derived growth factor receptor alpha-wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors

31 March 2020

1 reference

Molecular characterization of pediatric gastrointestinal stromal tumors.

31 March 2020

1 reference

Gastric stromal sarcoma, pulmonary chondroma, and extra-adrenal paraganglioma (Carney Triad): natural history, adrenocortical component, and possible familial occurrence

31 March 2020

1 reference

Chromosomal aberrations in malignant gastrointestinal stromal tumors: correlation with c-KIT gene mutation

31 March 2020

1 reference

Allelic loss of 14q and 22q, NF2 mutation, and genetic instability occur independently of c-kit mutation in gastrointestinal stromal tumor

31 March 2020

1 reference

Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations.

31 March 2020

1 reference

Putative chromosomal deletions on 9P, 9Q and 22Q occur preferentially in malignant gastrointestinal stromal tumors

31 March 2020

1 reference

High-resolution deletion mapping of chromosome 14 in stromal tumors of the gastrointestinal tract suggests two distinct tumor suppressor loci

31 March 2020

1 reference

Array comparative genomic hybridization analysis of chromosomal imbalances and their target genes in gastrointestinal stromal tumors

31 March 2020

1 reference

An oncogenetic tree model in gastrointestinal stromal tumours (GISTs) identifies different pathways of cytogenetic evolution with prognostic implications

31 March 2020

1 reference

Microsatellite DNA alterations of gastrointestinal stromal tumors are predictive for outcome.

31 March 2020

1 reference

Integrative genomic characterization and a genomic staging system for gastrointestinal stromal tumors

31 March 2020

1 reference

Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity

31 March 2020

1 reference

Neurofibromatosis type 1-related gastrointestinal stromal tumors: a special reference to loss of heterozygosity at 14q and 22q.

31 March 2020

1 reference

Gene expression profiling of human gastrointestinal stromal tumors according to its malignant potential.

31 March 2020

1 reference

High Prognostic Value of p16INK4 Alterations in Gastrointestinal Stromal Tumors

31 March 2020

1 reference

9p21 locus analysis in high-risk gastrointestinal stromal tumors characterized for c-kit and platelet-derived growth factor receptor alpha gene alterations.

31 March 2020

1 reference

Role of p16/INK4a in gastrointestinal stromal tumor progression

31 March 2020

1 reference

Loss of heterozygosity of chromosome 9p and loss of p16INK4A expression are associated with malignant gastrointestinal stromal tumors

31 March 2020

1 reference

Homozygous deletion of MTAP gene as a poor prognosticator in gastrointestinal stromal tumors

31 March 2020

1 reference

Prognostic significance of expressions of cell-cycle regulatory proteins in gastrointestinal stromal tumor and the relevance of the risk grade.

31 March 2020

1 reference

Cyclin D3 immunoreactivity in gastrointestinal stromal tumors is independent of cyclin D3 gene amplification and is associated with nuclear p27 accumulation

31 March 2020

1 reference

Cyclin H expression is increased in GIST with very-high risk of malignancy

31 March 2020

1 reference

The expression of p53 and bcl-2 in gastrointestinal stromal tumours is associated with anatomical site, and p53 expression is associated with grade and clinical outcome

31 March 2020

1 reference

Predicting Metastatic Risk of Gastrointestinal Stromal Tumors: Role of Cell Proliferation and Cell Cycle Regulatory Proteins

31 March 2020

1 reference

Cell cycle/apoptosis molecule expression correlates with imatinib response in patients with advanced gastrointestinal stromal tumors.

31 March 2020

1 reference

Patterns of gene amplification in gastrointestinal stromal tumors (GIST)

31 March 2020

1 reference

Down-regulation of miR-221 and miR-222 correlates with pronounced Kit expression in gastrointestinal stromal tumors

31 March 2020

1 reference

Kitlow stem cells cause resistance to Kit/platelet-derived growth factor alpha inhibitors in murine gastrointestinal stromal tumors

31 March 2020

1 reference

Germline mutation in the juxtamembrane domain of the kit gene in a family with gastrointestinal stromal tumors and urticaria pigmentosa

31 March 2020

1 reference

PDGFRA germline mutation in a family with multiple cases of gastrointestinal stromal tumor

31 March 2020

1 reference

Familial gastrointestinal stromal tumors associated with dysphagia and novel type germline mutation of KIT gene

31 March 2020

1 reference

Germline-activating mutation in the kinase domain of KIT gene in familial gastrointestinal stromal tumors

31 March 2020

1 reference

Familial gastrointestinal stromal tumor with hyperpigmentation: association with a germline mutation of the c-kit gene

31 March 2020

1 reference

Familial gastrointestinal stromal tumours with germline mutation of the KIT gene

31 March 2020

1 reference

DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumours.

31 March 2020

1 reference

Patterns of nestin and other intermediate filament expression distinguish between gastrointestinal stromal tumors, leiomyomas and schwannomas

31 March 2020

1 reference

PKC theta, a novel immunohistochemical marker for gastrointestinal stromal tumors (GIST), especially useful for identifying KIT-negative tumors

31 March 2020

1 reference

Specificity of DOG1 (K9 clone) and protein kinase C theta (clone 27) as immunohistochemical markers of gastrointestinal stromal tumour.

31 March 2020

1 reference

Protein kinases expressed by interstitial cells of Cajal

31 March 2020

1 reference

Localization of protein kinase C theta immunoreactivity to interstitial cells of Cajal in guinea-pig gastrointestinal tract

31 March 2020

1 reference

Ano1 is a selective marker of interstitial cells of Cajal in the human and mouse gastrointestinal tract

31 March 2020

1 reference

KIT 1530ins6 mutation defines a subset of predominantly malignant gastrointestinal stromal tumors of intestinal origin

31 March 2020

1 reference

Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations

31 March 2020

1 reference

KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size

31 March 2020

1 reference

High incidence of microscopic gastrointestinal stromal tumors in the stomach

31 March 2020

1 reference

Frequency, phenotype, and genotype of minute gastrointestinal stromal tumors in the stomach: an autopsy study.

31 March 2020

1 reference

Molecular and clinicopathologic characterization of gastrointestinal stromal tumors (GISTs) of small size

31 March 2020

1 reference

Microscopic gastrointestinal stromal tumors in esophageal and intestinal surgical resection specimens: a clinicopathologic, immunohistochemical, and molecular study of 19 lesions

31 March 2020

1 reference

Multiple Primary Sporadic Gastrointestinal Stromal Tumors in the Adult: An Underestimated Entity

31 March 2020

1 reference

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

31 March 2020

1 reference

KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients

31 March 2020

1 reference

Structure of a c-kit product complex reveals the basis for kinase transactivation

31 March 2020

1 reference

Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor

31 March 2020

1 reference

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

31 March 2020

1 reference

Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

31 March 2020

1 reference

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

31 March 2020

1 reference

Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients

31 March 2020

1 reference

Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial

31 March 2020

1 reference

Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial.

31 March 2020

1 reference

Autophagy inhibition and antimalarials promote cell death in gastrointestinal stromal tumor (GIST).

31 March 2020

1 reference

Pathologic and Molecular Heterogeneity in Imatinib-Stable or Imatinib-Responsive Gastrointestinal Stromal Tumors

31 March 2020

1 reference

Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs).

31 March 2020

1 reference

Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.

31 March 2020

1 reference

Highlighting the role of FDG PET scan in early response assessment of gastrointestinal stromal tumor treated with imatinib mesylate

31 March 2020

1 reference

Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncol

31 March 2020

1 reference

Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.

31 March 2020

1 reference

Histone H2AX Is a Mediator of Gastrointestinal Stromal Tumor Cell Apoptosis following Treatment with Imatinib Mesylate

31 March 2020

1 reference

Cancer. Addiction to oncogenes--the Achilles heal of cancer

31 March 2020

1 reference

Synergistic induction of apoptosis by the Bcl-2 inhibitor ABT-737 and imatinib mesylate in gastrointestinal stromal tumor cells

31 March 2020

1 reference

Role for the proapoptotic factor BIM in mediating imatinib-induced apoptosis in a c-KIT-dependent gastrointestinal stromal tumor cell line

31 March 2020

1 reference

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours

31 March 2020

1 reference

Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor

31 March 2020

1 reference

PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib

31 March 2020

1 reference

Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity

31 March 2020

1 reference

V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRA wild-type gastrointestinal stromal tumours.

31 March 2020

1 reference

Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors

31 March 2020

1 reference

Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib.

31 March 2020

1 reference

A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors

31 March 2020

1 reference

Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants

31 March 2020

1 reference

Resistance to imatinib, low-grade FDG-avidity on PET, and acquired KIT exon 17 mutation in gastrointestinal stromal tumour

31 March 2020

1 reference

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

31 March 2020

1 reference

Recurrent gastrointestinal stromal tumor (GIST) of the stomach associated with a novel c-kit mutation after imatinib treatment

31 March 2020

1 reference

Late resistance to imatinib therapy in a metastatic gastrointestinal stromal tumour is associated with a second KIT mutation

31 March 2020

1 reference

Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations

31 March 2020

1 reference

A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient

31 March 2020

1 reference

Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate

31 March 2020

1 reference

Heterogeneity of kinase inhibitor resistance mechanisms in GIST

31 March 2020

1 reference

Molecular analysis of secondary kinase mutations in imatinib-resistant gastrointestinal stromal tumors

31 March 2020

1 reference

Secondary mutations in the kinase domain of the KIT gene are predominant in imatinib-resistant gastrointestinal stromal tumor

31 March 2020

1 reference

Polyclonal Resistance in Gastrointestinal Stromal Tumor Treated with Sequential Kinase Inhibitors

31 March 2020

1 reference

Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors

31 March 2020

1 reference

Inhibition of focal adhesion kinase as a potential therapeutic strategy for imatinib-resistant gastrointestinal stromal tumor.

31 March 2020

1 reference

A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors

31 March 2020

1 reference

Differential properties of current tyrosine kinase inhibitors in gastrointestinal stromal tumors

31 March 2020

1 reference

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

31 March 2020

1 reference

Sunitinib-resistant gastrointestinal stromal tumors harbor cis-mutations in the activation loop of the KIT gene.

31 March 2020

1 reference

The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile

31 March 2020

1 reference

A phase I-II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors

31 March 2020

1 reference

Gastrointestinal Stromal Tumors, Intramural Leiomyomas, and Leiomyosarcomas in the Duodenum: A Clinicopathologic, Immunohistochemical, and Molecular Genetic Study of 167 Cases

31 March 2020

1 reference

Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up

31 March 2020

1 reference

Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up

31 March 2020

1 reference

Structure and organization of interstitial cells of Cajal in the gastrointestinal tract

31 March 2020

1 reference

Sorafenib Inhibits the Imatinib-Resistant KITT670I Gatekeeper Mutation in Gastrointestinal Stromal Tumor

31 March 2020

1 reference

Preclinical evaluation of nilotinib efficacy in an imatinib-resistant KIT-driven tumor model

31 March 2020

1 reference

Resistance to c-KIT kinase inhibitors conferred by V654A mutation

31 March 2020

1 reference

Deletion of the KIT gene is associated with liver metastasis and poor prognosis in patients with gastrointestinal stromal tumor in the stomach.

31 March 2020

1 reference

12 December 2020

Loss of p16 protein defines high-risk patients with gastrointestinal stromal tumors: a tissue microarray study

1 reference

12 December 2020

Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor.

1 reference

12 December 2020

Cytogenetic and morphologic characteristics of gastrointestinal stromal tumors. Recurrent rearrangement of chromosome 1 and losses of chromosomes 14 and 22 as common anomalies

1 reference

12 December 2020

Loss of heterozygosity at 1p36 predicts poor prognosis in gastrointestinal stromal/smooth muscle tumors

1 reference

12 December 2020

DNA sequence copy number changes in gastrointestinal stromal tumors: tumor progression and prognostic significance

1 reference

12 December 2020

DNA copy number losses in chromosome 14: an early change in gastrointestinal stromal tumors

1 reference

12 December 2020

Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors

1 reference

12 December 2020

Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal

1 reference

12 December 2020

Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor.

1 reference

12 December 2020

KIT mutation portends poor prognosis in gastrointestinal stromal/smooth muscle tumors

1 reference

12 December 2020

Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors

1 reference

12 December 2020

KIT activation is a ubiquitous feature of gastrointestinal stromal tumors

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRC3143

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22089421%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

16 January 2020

1020858724

0 references

1 reference